News for Nuvalent, Inc. (NUVL)

Summary Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company, announced on July 21, 2025, the dosing of the first patient in its global Phase 3 ALKAZ

PR NewswireCAMBRIDGE, Mass., July 21, 2025 CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutica

Nuvalent (ticker: NUVL) initiates the Phase 3 ALKAZAR trial to evaluate neladalkib in TKI-naïve ALK-positive NSCLC patients. The trial will enroll appr

Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent announced positive pivotal data from its global ARROS-1 Phase 1/2 clinical trial for zidesamtinib. The novel ROS1-selective inhibitor is being developed for TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer/NSCLC. […]

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprecedented” durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of th

Summary Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced on June 23, 2025, that it will host

Nuvalent (NASDAQ: NUVL) to present pivotal data on June 24, 2025, regarding zidesamtinib for ROS1-positive NSCLC The presentation will focus on TKI pre-

Summary Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced on June 18, 2025, the appointment o

Comprehensive SWOT analysis of Nuvalent Inc, revealing key strengths, weaknesses, opportunities, and threats.Financial scrutiny based on the latest 10-Q filing

PR NewswireCAMBRIDGE, Mass., April 29, 2025 CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceuti

Nuvalent (NUVL) revealed critical research for its ROS1-selective inhibitor, zidesamtinib, published in Molecular Cancer Therapeutics. The drug shows pr

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain positive […]

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Nuvalent, Inc.

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President […]

PR NewswireCAMBRIDGE, Mass., April 23, 2025 CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceuti

Nuvalent (NUVL) to present at the 2025 ASCO Annual Meeting from May 30 to June 5. ALKAZAR Phase 3 trial to compare neladalkib with ALECENSA® for ALK-po

Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today’s high-interest-rate environment. With […]

Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced on February 28, 2025, that its CEO, James P